Clinical Research

Zentralinstitut Fuer Seelische Gesundheit

Address
Luisenring J 5

Sponsor Overview

assignment
3
sponsored trials
science
2
molecules
location_city
2
research centres
public
1
country
person_search
4
investigators

Specializations

Psychotic Disorders and Schizophrenia

The sponsor’s clinical research includes schizophrenia, schizophrenia spectrum disorders, and other primary psychotic disorders, with interest in symptom control and functional recovery in early and remitted illness.

  • Antipsychotic maintenance treatment
  • Early-phase schizophrenia
  • Schizophrenia spectrum disorders

Research activity in this area is centered in psychiatric care and focuses on adjunctive approaches for persistent symptoms and social functioning.

Cannabidiol in Psychiatric Treatment

The sponsor studies cannabidiol as an add-on intervention in schizophrenia and alcohol dependence, reflecting interest in non-standard therapeutic options within mental health and addiction care.

  • Cannabidiol
  • Add-on therapy
  • Antipsychotic treatment

This area links psychiatry with substance-related disorder research and supports exploration of symptom-oriented adjunctive therapies.

Oxytocin and Social Functioning

Another focus is intranasal oxytocin in schizophrenia spectrum disorders, with attention to psychosocial outcomes and social skill support alongside routine care.

  • Intranasal oxytocin
  • Psychosocial treatment
  • Social skills

The therapeutic interest lies in interventions that may complement psychosocial treatment for patients with enduring social and interpersonal difficulties.

Alcohol Dependence and Craving Reduction

The sponsor also funds research in alcohol dependence, with a clear focus on craving reduction and treatment support for patients receiving standard addiction therapy.

  • Alcohol craving
  • Naltrexone
  • Substance use disorder

This research area combines addiction medicine with interest in adjunctive pharmacological strategies for persistent craving.

Sponsored Trials

Trial Name Country Status
A Randomized, Double-Blind, Placebo-Controlled Trial of Cannabidiol as an Adjunct to Antipsychotic Therapy in Remitted Early Phase SchizophreniaGermany GermanyNot Yet Recruiting
Evaluation of Cannabidiol and Naltrexone on Cue-Induced Alcohol Craving in Alcohol Dependence: A Randomized, Double-Blind, Placebo-Controlled TrialGermany GermanyRecruiting
Randomized, Double-Blind Trial of Intranasal Oxytocin as an Adjunct to Psychosocial Treatment in Schizophrenia Spectrum DisordersGermany GermanyNot Yet Recruiting

Data & Insights

science
Molecule Portfolio
Compounds under investigation
0
Exclusive Molecules
out of 2 total (0% not shared with other sponsors)

This sponsor works with 2 molecules, of which 0 are not being studied by other sponsors.

hub
Site Partnerships
Collaboration with research centres
50%
Return partnership rate
1 of 2 sites collaborated multiple times

This sponsor has worked with 2 sites across their trial portfolio.

Therapeutic Focus

  • 1.
    Mental Disorders3 trials
    150 other sponsors

Partnered Research Centres

2 centres
location_city
assignment29
Central Institute of Mental Health
Address
Luisenring J 5, 68159 Mannheim
Learn morearrow_forward
location_city
assignment1
Psychiatrisches Zentrum Nordbaden
Address
Heidelberger Straße 1A, 69168 Wiesloch
Learn morearrow_forward

Want to get in touch with this sponsor?

Send a question and we'll pass it on to Zentralinstitut Fuer Seelische Gesundheit.

Need a custom report on this sponsor?

Competitive positioning, market entry, partnership opportunities — tell us the question.

Is something out of date?

Tell us what needs correcting and we'll update this profile.